Short summary

Lead4Life is a public-private partnership program focused on enabling both the GMP-grade availability and the clinical applicability of the promising medical isotope lead-212. By developing scalable production processes and enabling technologies, the program supports the development of new radiopharmaceuticals and accelerates their future use in cancer care.

Program coordinator
KWF Kankerbestrijding
Ralph Geuskens
R.Geuskens@kwf.nl
Program group
KWF, NRG PALLAS, FAST and the Oncode Institute
PPP subsidy
€5.000.000,-
Lead4Life

Lead4Life

Making lead-212 widely available and enabling its use in radiopharmaceuticals for cancer patients.

Lead4Life is a newly established public-private partnership program in which KWF, NRG PALLAS, FAST and the Oncode Institute combine their strengths. The program focuses on making the promising medical isotope lead-212 available at GMP quality, while simultaneously developing the technologies needed to enable its use in new radiopharmaceuticals and, ultimately, in cancer care.

Cancer remains one of the leading causes of death worldwide, and for many patients current treatment options are still limited. Radiopharmaceutical therapies already show clear benefits for certain cancers. Lead-212 is an alpha-emitting isotope with high energy delivered over a very short distance, offering the potential for even more effective and precise cancer treatments. However, global availability of lead-212 is extremely limited, which slows down research, innovation and access for patients. At the same time, the growing international market for radiopharmaceuticals offers significant economic opportunities for countries with strong nuclear and medical infrastructure.

Lead4Life addresses these challenges by focusing on two closely connected pillars. First, the program develops scalable and non-exclusive production processes to make lead-212 available at GMP quality. Second, it supports the development of enabling technologies such as dosimetry, imaging, radiation safety and waste management. Together, these activities make it possible for researchers and companies to develop new lead-212-based radiopharmaceuticals and to prepare their safe and effective application in healthcare. By taking a programmatic, chain-oriented approach, Lead4Life accelerates innovation from laboratory research towards future clinical use.

Lead4Life will implement an open call for public-private partnership projects. FAST will organize an online information session on Wednesday 4 March, 15:30–17:00, followed by a matchmaking event on Wednesday afternoon, 8 April 2026, to support consortium formation and thematic alignment. Project proposals will be selected through an evaluation procedure coordinated by KWF. More information and registration links will be communicated via the program partners’ websites and newsletters.

Date
Action
4 March 2026
Online information session
8 April 2026
Matchmaking meeting
May 2026
Opening of the call for PPS project proposals
22 September 2026
Closing of the call for PPS project proposals
February 2027
Funding decision